Price
No data yet.
Social Signal Score
Revenue
$3.17M-4.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alfred W. Sandrock Jr.
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 141
- Beta
- 1.32
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.65
Financials
Revenue
$3.17M-4.3%Net Income
$-24.47MEBITDA
$-22.61MFree Cash Flow
$-25.84MEPS (diluted)
$-0.40Shares Outstanding (diluted)
60.55M+138.6%Operating Expenses
$29.56MCash & Debt
$116.34MReturn of Capital
$0.00Revenue by Segment (annual)
$5.50MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $40.37M | $-119.72M | $-2.04 |
| 2024 | $80.00M | $-65.00M | $-1.13 |
| 2023 | $250.01M | $132.33M | $3.08 |
| 2022 | $40.91M | $-46.41M | $-1.21 |
| 2021 | $37.41M | $-71.20M | $-1.75 |
| 2020 | $171.13M | $36.74M | $0.99 |
| 2019 | $104.39M | $-43.60M | $-1.14 |
| 2018 | $7.62M | $-88.29M | $-2.75 |
| 2017 | $10.13M | $-70.70M | $-2.64 |
| 2016 | $14.22M | $-40.19M | $-1.59 |
| 2015 | $17.33M | $-29.67M | $-7.08 |
| 2014 | $0.00 | $-16.32M | $-1.11 |
| 2013 | $0.00 | $-7.67M | $-16.55 |
Valuation
VYGRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·6h ago·Positive
Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·9d ago·Neutral
Voyager to Present at Upcoming Investor Conferences LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m.
View source ↗
Earnings
Mon, Nov 9(in 2 months)
Consensus estimate $-0.41 per share
Typical surprise +11.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.40 vs $-0.48beat
- Thu, May 7$-0.47 vs $-0.54beat
- Mon, Mar 9$-0.46 vs $-0.54beat
- Mon, Nov 10$-0.47 vs $-0.53beat
- Wed, Aug 6$-0.57 vs $-0.48miss
- Tue, May 6$-0.53 vs $-0.35miss
Estimates and results for VYGR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VYGR officers and directors.
- Bought
- —
- Sold
- $1.1m
0 trades
33 trades
- Sandrock Alfredsold
- Swartz Robinsold
- Sandrock Alfredsold
- Jorgensen Nathan D.sold
- Carter Todd Alfredsold
- Swartz Robinsold
- Carter Todd Alfredsold
- Sandrock Alfredsold
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.